<DOC>
	<DOCNO>NCT00489359</DOCNO>
	<brief_summary>The purpose study determine efficacy combination therapy pemetrexed carboplatin treatment patient platinum-sensitive ovarian cancer . This study also include patient primary peritoneal cancer .</brief_summary>
	<brief_title>Trial Pemetrexed Carboplatin Patients With Recurrent Ovarian Primary Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis ovarian primary peritoneal cancer confirm pathology Patients must recurrent ovarian cancer sensitive platinum therapy Prior radiation therapy allow Measurable disease define Response Evaluation Criteria In Solid Tumors ( RECIST ) guideline , nonmeasurable cancer antigen 125 ( CA125 ) great equal 2X upper limit . More 2 line therapy ovarian primary peritoneal cancer . Pregnant breast feeding . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>